Depression drug studied for pancreatic cancer patients – trial cut short
NCT ID NCT05289830
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tested whether the antidepressant escitalopram could reduce depression in people with localized pancreatic cancer who were receiving chemotherapy before surgery. Only 4 participants were enrolled before the trial was stopped early. The goal was to see if the drug improved mood and quality of life compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.